26.70
+0.11(+0.41%)
Currency In USD
Address
250 East Grand Avenue
South San Francisco, CA 94080
United States of America
Phone
650 338 3533
Website
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
October 25, 2024
| Name | Title | Pay | Year Born |
| Jeffrey T. Finer | Co-Founder, CEO & Director | 919,071 | 1967 |
| Jae Kim | Chief Medical Officer | 486,288 | 1970 |
| Samira Shaikhly | Chief People Officer | 536,487 | 1970 |
| Elizabeth Bhatt | President & Chief Operating Officer | 661,829 | 1968 |
| Arthur Christopoulos | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 0 | N/A |
| Patrick Sexton | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 0 | N/A |
| Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | 0 | 1944 |
| George Xu | Senior Director of Corporate Development & Portfolio Strategy | 0 | N/A |
| Gilbert Labrucherie | Chief Financial Officer | 0 | 1972 |
| Richard Hansen | Vice President of Technology | 0 | N/A |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.